Related Experiment Videos
Indomethacin for recurrent cutaneous necrotizing eosinophilic vasculitis
Chuchai Tanglertsampan1, Niyom Tantikun, Nopadon Noppakun
1Skin Center, Bum- rungrad International Hospital, 33 Sukhumvit 3, Wattana, Bangkok 10110, Thailand. drchuchait@yahoo.com
Summary
Recurrent cutaneous necrotizing eosinophilic vasculitis (RCNEV) is a rare condition. This case study shows indomethacin as a potential treatment option for RCNEV, offering an alternative to corticosteroids.
Area of Science:
- Dermatology
- Rheumatology
Background:
- Recurrent cutaneous necrotizing eosinophilic vasculitis (RCNEV) is a rare vasculitis.
- RCNEV presents with pruritic purpuric papules and angioedema.
- Skin biopsies show eosinophil-predominate necrotizing vasculitis in small dermal vessels.
Observation:
- Systemic corticosteroids are effective but have side effects.
- A case of RCNEV was successfully treated with indomethacin.
- This is the first reported case of RCNEV treated with indomethacin.
Findings:
- Indomethacin effectively managed RCNEV symptoms.
- The patient tolerated indomethacin well.
- No adverse effects were noted with indomethacin treatment.
Implications:
- Indomethacin may be a viable alternative treatment for RCNEV.
- Further research is needed to confirm indomethacin's efficacy and safety in RCNEV.
- This finding could lead to new therapeutic strategies for patients with RCNEV.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:18Endocarditis III: Medical Management
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...